TY - JOUR AU - Liebl, A. PY - 2007 DA - 2007// TI - Kosten in der Früh- und Spätphase des Diabetes mellitus [Costs involved in the early and late phases of diabetes mellitus.] JO - Internist (Berl) VL - 48 UR - https://doi.org/10.1007/s00108-007-1875-0 DO - 10.1007/s00108-007-1875-0 ID - Liebl2007 ER - TY - JOUR AU - Köster, I. AU - von Ferber, L. AU - Ihle, P. AU - Schubert, I. AU - Hauner, H. PY - 2006 DA - 2006// TI - The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study JO - Diabetologia VL - 49 UR - https://doi.org/10.1007/s00125-006-0277-5 DO - 10.1007/s00125-006-0277-5 ID - Köster2006 ER - TY - JOUR AU - Köster, I. AU - Hauner, H. AU - von Ferber, L. PY - 2006 DA - 2006// TI - Heterogenität der Kosten bei Patienten mit Diabetes mellitus: Die KoDiM-Studie [Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study] JO - Dtsch Med Wochenschr VL - 131 UR - https://doi.org/10.1055/s-2006-939850 DO - 10.1055/s-2006-939850 ID - Köster2006 ER - TY - JOUR AU - Liebl, A. AU - Neiss, A. AU - Spannheimer, A. AU - Reitberger, U. AU - Wagner, T. AU - Görtz, A. PY - 2001 DA - 2001// TI - Kosten des Typ-2-Diabetes in Deutschland [Costs of type 2 diabetes in Germany. Results of the CODE-2 study] JO - Dtsch Med Wochenschr VL - 126 UR - https://doi.org/10.1055/s-2001-14102 DO - 10.1055/s-2001-14102 ID - Liebl2001 ER - TY - JOUR AU - Yurgin, N. AU - Secnik, K. AU - Lage, M. J. PY - 2007 DA - 2007// TI - Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study JO - Clin Ther VL - 29 UR - https://doi.org/10.1016/j.clinthera.2007.02.012 DO - 10.1016/j.clinthera.2007.02.012 ID - Yurgin2007 ER - TY - JOUR AU - Pittrow, D. AU - Stalla, G. K. AU - Zeiher, A. M. AU - Silber, S. AU - März, W. AU - Pieper, L. PY - 2006 DA - 2006// TI - [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care] JO - Med Klin (Munich) VL - 101 UR - https://doi.org/10.1007/s00063-006-1093-x DO - 10.1007/s00063-006-1093-x ID - Pittrow2006 ER - TY - JOUR AU - Schneider, C. A. AU - Herold, G. AU - Gysan, D. AU - Albus, C. AU - Bjarnason-Wehrens, B. AU - Predel, H. G. PY - 2007 DA - 2007// TI - Prevalence of cardiovascular risk factors in middle-aged type 2 diabetic automobile employees assessed at the workplace – the Praeford study JO - J Occup Environ Med VL - 49 UR - https://doi.org/10.1097/JOM.0b013e3180577750 DO - 10.1097/JOM.0b013e3180577750 ID - Schneider2007 ER - TY - JOUR AU - Krentz, A. J. AU - Bailey, C. J. PY - 2005 DA - 2005// TI - Oral antidiabetic agents: current role in type 2 diabetes mellitus JO - Drugs VL - 65 UR - https://doi.org/10.2165/00003495-200565030-00005 DO - 10.2165/00003495-200565030-00005 ID - Krentz2005 ER - TY - JOUR AU - Miyazaki, Y. AU - Mahankali, A. AU - Matsuda, M. AU - Glass, L. AU - Mahankali, S. AU - Ferrannini, E. PY - 2001 DA - 2001// TI - Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone JO - Diabetes Care VL - 24 UR - https://doi.org/10.2337/diacare.24.4.710 DO - 10.2337/diacare.24.4.710 ID - Miyazaki2001 ER - TY - JOUR AU - Goldberg, R. B. AU - Kendall, D. M. AU - Deeg, M. A. AU - Buse, J. B. AU - Zagar, A. J. AU - Pinaire, J. A. PY - 2005 DA - 2005// TI - A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia JO - Diabetes Care VL - 28 UR - https://doi.org/10.2337/diacare.28.7.1547 DO - 10.2337/diacare.28.7.1547 ID - Goldberg2005 ER - TY - JOUR AU - Aljabri, K. AU - Kozak, S. E. AU - Thompson, D. M. PY - 2004 DA - 2004// TI - Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial JO - Am J Med VL - 116 UR - https://doi.org/10.1016/j.amjmed.2003.07.023 DO - 10.1016/j.amjmed.2003.07.023 ID - Aljabri2004 ER - TY - JOUR AU - Hanefeld, M. AU - Pfützner, A. AU - Forst, T. AU - Lübben, G. PY - 2006 DA - 2006// TI - Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study JO - Curr Med Res Opin VL - 22 UR - https://doi.org/10.1185/030079906X112598 DO - 10.1185/030079906X112598 ID - Hanefeld2006 ER - TY - JOUR AU - Derosa, G. AU - Cicero, A. F. AU - Gaddi, A. AU - Ragonesi, P. D. AU - Fogari, E. AU - Bertone, G. PY - 2004 DA - 2004// TI - Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial JO - Clin Ther VL - 26 UR - https://doi.org/10.1016/S0149-2918(04)90074-4 DO - 10.1016/S0149-2918(04)90074-4 ID - Derosa2004 ER - TY - JOUR AU - Gastaldelli, A. AU - Ferrannini, E. AU - Miyazaki, Y. AU - Matsuda, M. AU - Mari, A. AU - DeFronzo, R. A. PY - 2007 DA - 2007// TI - Thiazolidinediones improve beta-cell function in type 2 diabetic patients JO - Am J Physiol Endocrinol Metab VL - 292 UR - https://doi.org/10.1152/ajpendo.00551.2006 DO - 10.1152/ajpendo.00551.2006 ID - Gastaldelli2007 ER - TY - STD TI - European Medicines Agency: Post-Authorisation summary of positive opinion for Glustin (pioglitazone).[http://www.emea.europa.eu/pdfs/human/press/pr/256803en.pdf] UR - http://www.emea.europa.eu/pdfs/human/press/pr/256803en.pdf ID - ref15 ER - TY - JOUR AU - Charbonnel, B. AU - Dormandy, J. AU - Erdmann, E. AU - Massi-Benedetti, M. AU - Skene, A. PY - 2004 DA - 2004// TI - The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients JO - Diabetes Care VL - 27 UR - https://doi.org/10.2337/diacare.27.7.1647 DO - 10.2337/diacare.27.7.1647 ID - Charbonnel2004 ER - TY - JOUR AU - Dormandy, J. A. AU - Charbonnel, B. AU - Eckland, D. J. AU - Erdmann, E. AU - Massi-Benedetti, M. AU - Moules, I. K. PY - 2005 DA - 2005// TI - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial JO - Lancet VL - 366 UR - https://doi.org/10.1016/S0140-6736(05)67528-9 DO - 10.1016/S0140-6736(05)67528-9 ID - Dormandy2005 ER - TY - JOUR AU - Kahn, S. E. AU - Haffner, S. M. AU - Heise, M. A. AU - Herman, W. H. AU - Holman, R. R. AU - Jones, N. P. PY - 2006 DA - 2006// TI - Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa066224 DO - 10.1056/NEJMoa066224 ID - Kahn2006 ER - TY - JOUR AU - Palmer, A. J. AU - Roze, S. AU - Valentine, W. J. AU - Minshall, M. E. AU - Foos, V. AU - Lurati, F. M. PY - 2004 DA - 2004// TI - The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement mecision-making JO - Current Medical Research and Opinion VL - 20 UR - https://doi.org/10.1185/030079904X1980 DO - 10.1185/030079904X1980 ID - Palmer2004 ER - TY - JOUR AU - Palmer, A. J. AU - Roze, S. AU - Valentine, W. AU - Minshall, M. AU - Foos, V. AU - Lurati, F. PY - 2004 DA - 2004// TI - Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies JO - Current Medical Research and Opinion VL - 20 UR - https://doi.org/10.1185/030079904X2006 DO - 10.1185/030079904X2006 ID - Palmer2004 ER - TY - JOUR AU - Valentine, W. J. AU - Bottomley, J. AU - Palmer, A. J. AU - Brandle, M. AU - Foos, V. AU - Williams, R. PY - 2007 DA - 2007// TI - PROactive 06: Cost effectiveness of pioglitazone in type 2 diabetes in the UK JO - Diabetic Medicine VL - 24 UR - https://doi.org/10.1111/j.1464-5491.2007.02188.x DO - 10.1111/j.1464-5491.2007.02188.x ID - Valentine2007 ER - TY - JOUR AU - Leibson, C. L. AU - O'Brien, P. C. AU - Atkinson, E. AU - Palumbo, P. J. AU - Melton, L. J. PY - 1997 DA - 1997// TI - Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study JO - Am J Epidemiol VL - 146 UR - https://doi.org/10.1093/oxfordjournals.aje.a009187 DO - 10.1093/oxfordjournals.aje.a009187 ID - Leibson1997 ER - TY - JOUR PY - 1995 DA - 1995// TI - U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease JO - Diabetes VL - 44 UR - https://doi.org/10.2337/diab.44.11.1249 DO - 10.2337/diab.44.11.1249 ID - ref23 ER - TY - JOUR AU - Murabito, J. M. AU - D'Agostino, R. B. AU - Silbershatz, H. AU - Wilson, W. F. PY - 1997 DA - 1997// TI - Intermittent claudication. A risk profile from The Framingham Heart Study JO - Circulation VL - 96 UR - https://doi.org/10.1161/01.CIR.96.1.44 DO - 10.1161/01.CIR.96.1.44 ID - Murabito1997 ER - TY - JOUR AU - Kannel, W. B. AU - D'Agostino, R. B. AU - Silbershatz, H. AU - Belanger, A. J. AU - Wilson, P. W. AU - Levy, D. PY - 1999 DA - 1999// TI - Profile for estimating risk of heart failure JO - Arch Intern Med VL - 159 UR - https://doi.org/10.1001/archinte.159.11.1197 DO - 10.1001/archinte.159.11.1197 ID - Kannel1999 ER - TY - JOUR AU - Stevens, R. J. AU - Kothari, V. AU - Adler, A. I. AU - Stratton, I. M. AU - Holman, R. R. PY - 2001 DA - 2001// TI - The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) JO - Clin Sci (Lond) VL - 101 UR - https://doi.org/10.1042/cs1010671 DO - 10.1042/cs1010671 ID - Stevens2001 ER - TY - JOUR AU - Kothari, V. AU - Stevens, R. J. AU - Adler, A. I. AU - Stratton, I. M. AU - Manley, S. E. AU - Neil, H. A. PY - 2002 DA - 2002// TI - UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine JO - Stroke VL - 33 UR - https://doi.org/10.1161/01.STR.0000020091.07144.C7 DO - 10.1161/01.STR.0000020091.07144.C7 ID - Kothari2002 ER - TY - STD TI - NICE: National Institute for Clinical Excellence. Guide to the technology appraisal process.[http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf] UR - http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf ID - ref28 ER - TY - JOUR AU - Graf von der Schulenburg, J. M. AU - Greiner, W. AU - Jost, F. PY - 2007 DA - 2007// TI - Deutsche empfehlungen zur gesundheits-ökonomischen evaluation – dritte and aktualisierte fassung des Hannoveraner konsens JO - Gesundh okon Qual Manag VL - 12 UR - https://doi.org/10.1055/s-2007-963505 DO - 10.1055/s-2007-963505 ID - Graf von der Schulenburg2007 ER - TY - JOUR AU - Rathmann, W. AU - Haastert, B. AU - Icks, A. AU - Giani, G. PY - 2007 DA - 2007// TI - Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994–2004 JO - Diabetes Care VL - 30 UR - https://doi.org/10.2337/dc06-2000 DO - 10.2337/dc06-2000 ID - Rathmann2007 ER - TY - JOUR AU - Bagust, A. AU - Beale, S. PY - 2005 DA - 2005// TI - Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data JO - Health Econ VL - 14 UR - https://doi.org/10.1002/hec.910 DO - 10.1002/hec.910 ID - Bagust2005 ER - TY - JOUR AU - Tarn, T. AU - Smith, M. PY - 2004 DA - 2004// TI - Pharmacoeconomic Guidelines Around the World JO - ISPOR Connections VL - 10 ID - Tarn2004 ER - TY - JOUR PY - 1998 DA - 1998// TI - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) JO - Lancet VL - 352 UR - https://doi.org/10.1016/S0140-6736(98)07019-6 DO - 10.1016/S0140-6736(98)07019-6 ID - ref33 ER - TY - JOUR AU - Holstein, A. AU - Plaschke, A. AU - Egberts, E. H. PY - 2002 DA - 2002// TI - Incidence and costs of severe hypoglycemia JO - Diabetes Care VL - 25 UR - https://doi.org/10.2337/diacare.25.11.2109 DO - 10.2337/diacare.25.11.2109 ID - Holstein2002 ER - TY - JOUR AU - Clarke, P. AU - Gray, A. AU - Holman, R. PY - 2002 DA - 2002// TI - Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) JO - Med Decis Making VL - 22 UR - https://doi.org/10.1177/027298902400448902 DO - 10.1177/027298902400448902 ID - Clarke2002 ER - TY - JOUR AU - Scuffham, P. A. AU - Chaplin, S. PY - 2005 DA - 2005// TI - A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention JO - Clin Ther VL - 27 UR - https://doi.org/10.1016/j.clinthera.2005.09.012 DO - 10.1016/j.clinthera.2005.09.012 ID - Scuffham2005 ER - TY - JOUR AU - Briggs, A. H. AU - Wonderling, D. E. AU - Mooney, C. Z. PY - 1997 DA - 1997// TI - Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation JO - Health Econ VL - 6 UR - https://doi.org/3.0.CO;2-W DO - 3.0.CO;2-W ID - Briggs1997 ER - TY - JOUR AU - Köster, I. AU - von Ferber, L. AU - Ihle, P. AU - Schubert, I. AU - Hauner, H. PY - 2006 DA - 2006// TI - The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study JO - Diabetologia VL - 49 UR - https://doi.org/10.1007/s00125-006-0277-5 DO - 10.1007/s00125-006-0277-5 ID - Köster2006 ER - TY - STD TI - Wascher TC, (Eds): Diabetes Mellitus – How to prevent macrovascular disease?Journal für Kardiol 2003, 10: 149–151. ID - ref39 ER - TY - JOUR AU - Walter, H. AU - Lübben, G. PY - 2005 DA - 2005// TI - Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus JO - Drugs VL - 65 UR - https://doi.org/10.2165/00003495-200565010-00001 DO - 10.2165/00003495-200565010-00001 ID - Walter2005 ER - TY - JOUR AU - Schwappach, D. L. AU - Boluarte, T. A. PY - 2007 DA - 2007// TI - HEE-GER: a systematic review of German economic evaluations of health care published 1990–2004 JO - BMC Health Serv Res VL - 7 UR - https://doi.org/10.1186/1472-6963-7-7 DO - 10.1186/1472-6963-7-7 ID - Schwappach2007 ER - TY - JOUR AU - Eichler, H. G. AU - Kong, S. X. AU - Gerth, W. C. AU - Mavros, P. AU - Jonsson, B. PY - 2004 DA - 2004// TI - Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? JO - Value in Health VL - 7 UR - https://doi.org/10.1111/j.1524-4733.2004.75003.x DO - 10.1111/j.1524-4733.2004.75003.x ID - Eichler2004 ER - TY - STD TI - Dutch Council for Public Health and Health Care. Sensible and sustainable care[http://www.rvz.net/data/download/Advies_DenZ_samenvatting_engels.doc] UR - http://www.rvz.net/data/download/Advies_DenZ_samenvatting_engels.doc ID - ref43 ER - TY - STD TI - Lucas Goossens. Euro 80,000 per QALY is the limit. Institute for Medical Technology assessment[http://www.imta.nl/publications/imta_newsletter_4_1.pdf] UR - http://www.imta.nl/publications/imta_newsletter_4_1.pdf ID - ref44 ER - TY - JOUR AU - Devlin, N. AU - Parkin, D. PY - 2004 DA - 2004// TI - Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis JO - Health Econ VL - 13 UR - https://doi.org/10.1002/hec.864 DO - 10.1002/hec.864 ID - Devlin2004 ER - TY - JOUR AU - Walker, S. AU - Palmer, S. AU - Sculpher, M. PY - 2007 DA - 2007// TI - The role of NICE technology appraisal in NHS rationing JO - Br Med Bull VL - 81–82 UR - https://doi.org/10.1093/bmb/ldm007 DO - 10.1093/bmb/ldm007 ID - Walker2007 ER - TY - JOUR AU - Bryan, S. AU - Williams, I. AU - McIver, S. PY - 2007 DA - 2007// TI - Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals JO - Health Econ VL - 16 UR - https://doi.org/10.1002/hec.1133 DO - 10.1002/hec.1133 ID - Bryan2007 ER - TY - JOUR AU - Nitschmann, S. AU - Seufert, J. PY - 2007 DA - 2007// TI - [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)] JO - Internist (Berl) VL - 48 UR - https://doi.org/10.1007/s00108-006-1777-6 DO - 10.1007/s00108-006-1777-6 ID - Nitschmann2007 ER - TY - STD TI - Institute for Gesundheit und sozialforschung[http://www.iges.de] UR - http://www.iges.de ID - ref49 ER - TY - STD TI - DRG prices in Germany 2005 ID - ref50 ER - TY - JOUR AU - Voelkl, M. AU - Pirk, O. AU - Juenger, V. PY - 2005 DA - 2005// TI - Cost-effectiveness of candesartan in Germany for patients with chronic heart failure JO - Value in Health VL - 8 UR - https://doi.org/10.1016/S1098-3015(10)67438-4 DO - 10.1016/S1098-3015(10)67438-4 ID - Voelkl2005 ER - TY - JOUR AU - Laaser, U. AU - Breckenkamp, J. AU - Niermann, U. PY - 1999 DA - 1999// TI - Cost-effectiveness analysis of medical interventions in patients with stroke in Germany under special consideration of "stroke units" JO - Gesundh okon Qual Manag VL - 4 ID - Laaser1999 ER - TY - JOUR AU - Dahmen, H. G. PY - 1997 DA - 1997// TI - [Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae] JO - Gesundheitswesen VL - 59 ID - Dahmen1997 ER - TY - STD TI - Köhler A: Kölner Kommentar zum EBM 2002. Kölné Deutscher Ärzte-Verlag; ID - ref54 ER - TY - CHAP AU - Andersen, H. H. AU - Schwarze, J. PY - 2003 DA - 2003// BT - Bedarfsprofile in der gesetzlichen Krankenversicherung (GKV) [Requirement profiles of statutory health insurance] ID - Andersen2003 ER - TY - CHAP PY - 1998 DA - 1998// BT - Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland PB - Metzler Poeschel CY - Stuttgart ID - ref56 ER - TY - CHAP PY - 1998 DA - 1998// BT - Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland PB - Metzler Poeschel CY - Stuttgart ID - ref57 ER - TY - JOUR AU - Schädlich, P. K. AU - Brecht, J. G. AU - Brunetti, M. AU - Pagano, E. AU - Rangoonwala, B. AU - Huppertz, E. PY - 2001 DA - 2001// TI - Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance JO - Pharmacoeconomics VL - 19 UR - https://doi.org/10.2165/00019053-200119050-00005 DO - 10.2165/00019053-200119050-00005 ID - Schädlich2001 ER - TY - CHAP AU - Kelm-Kahl, I. AU - Ohrloff, C. PY - 2001 DA - 2001// BT - Minimal invasive Chirurgie beim Grauen Star: Was zahlt die Kassee-Medizin and Gesdunheit ID - Kelm-Kahl2001 ER - TY - JOUR AU - Ghatnekar, O. PY - 2002 DA - 2002// TI - Cost-Effectiveness of treating deep diabetic foot ulcers with Promogran in four different European countries JO - Journal of wound care VL - 11 UR - https://doi.org/10.12968/jowc.2002.11.2.26675 DO - 10.12968/jowc.2002.11.2.26675 ID - Ghatnekar2002 ER -